<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548352</url>
  </required_header>
  <id_info>
    <org_study_id>BASEL IX</org_study_id>
    <nct_id>NCT01548352</nct_id>
  </id_info>
  <brief_title>BAsel Syncope EvaLuation (BASEL IX) Study</brief_title>
  <official_title>BAsel Syncope EvaLuation (BASEL IX) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Syncope is a major health problem. In the emergency department (ED), the management of
      patients with syncope still remains a clinical challenge because underlying diseases and
      prognosis can be extremely various. Structural heart disease and primary electrical disorders
      are major risk factors for sudden cardiac death and mortality in patients with syncope. In
      contrast, patients with reflex syncope and exclusion of structural heart disease have an
      excellent prognosis.

      Therefore The investigators test the hypothesis that the use of a meticulous patient history,
      clinical examination and novel biomarkers can improve the rapid and accurate diagnosis of
      cardiac syncope in patients presenting to the ED and is able to improve risk stratification
      regarding adverse outcomes.

      The prospective multicenter cohort study is designed to enroll 720 patients presenting with
      transient loss of consciousness within the last 12 hours to the ED. Blood samples for the
      measurement of novel biomarkers will be obtained at presentation.

      All patients will be contacted by phone at 6, 12 and 24 months to determine major adverse
      events (death, resuscitation, recurrence of syncope, hospitalization for syncope).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Management of patients with syncope is a serious problem concerning 1-2% of
      emergency department (ED) visits. In 6-20% of these, syncope will be due to a cardiac origin.
      The rapid and accurate identification of these patients is an important unmet clinical need.

      Aim: The aim of the study is to evaluate the diagnostic value of patient's history, clinical
      judgement and novel biomarkers, alone or in combination, in the diagnosis and risk
      stratification of patients &gt; 40 years of age presenting with syncope to the ED.

      Patients and Methods: This prospective, observational, international multicenter study is
      initially designed to enroll 720 adult patients &gt; 40 years presenting to the ED with syncope
      within the last twelve hours. Patient history will be standardized using a predefined form.
      Treating physicians will be asked to quantify their clinical judgment regarding the presence
      of cardiac syncope. Digital 12-lead ECG will be recorded at presentation and stored
      electronically. Blood samples for the measurement of novel cardiovascular biomarkers
      (including copeptin, pro-endothelin-1, pro-adrenomedullin, natriuretic peptides and
      high-sensitive cardiac troponins) will be obtained at presentation and stored anonymized.
      Patients will be contacted by phone at 6, 12 and 24 months to determine major adverse events
      (death, resuscitation, recurrence of syncope, hospitalization for syncope) and results of
      follow-up examinations. The final diagnosis will be adjudicated by two independent experts
      after review of all documents pertaining to the individual patient after 6 months. The
      primary endpoint is to assess the performance of a standardized form of patient's history,
      clinical judgment and biomarkers, alone and in combination, in the diagnosis of a cardiac
      syncope, as adjudicated by two independent experts. Secondary endpoints include the accuracy
      of the above cited items in prognostic stratification and the determination of the
      cost-effectiveness of the best approach.

      Clinical significance: A more accurate and more rapid diagnosis and risk stratification of
      cardiac syncope can significantly improve patient management and therefore reduce patient
      morbidity and treatment cost. Overall, we expect this study to provide novel insights,
      holding important scientific, clinical and economic implications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic and prognostic value of various novel and established biomarkers, clinical assessment and detailed patient history</measure>
    <time_frame>within 24 months</time_frame>
    <description>To test the diagnostic performance of predefined elements of a standardized patient history, overall clinical judgement using a visual analogue scale, and novel biomarkers in the diagnosis of cardiac syncope in patients presenting to the ED.</description>
  </primary_outcome>
  <enrollment type="Anticipated">3500</enrollment>
  <condition>Syncope</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA Plasma; Heparin; Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting to the emergency department with syncope within the last 12 hours.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting to the emergency department

          -  Age &gt; 40 years

          -  Syncope within the last 12 hours

          -  Written informed consent

        Exclusion Criteria:

          -  Age &lt; 40 years

          -  Patients without loss of consciousness and with certain neurological causes (e.g.
             recurrent epilepsy, hemiplegia at presentation)

          -  No written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Mueller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Mueller, MD</last_name>
    <phone>0041-61-2652525</phone>
    <email>christian.mueller@usb.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Cardiovascular de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1428</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan P Constable, MD</last_name>
    </contact>
    <investigator>
      <last_name>Juan P Constable, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alan Sigal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's hospital</name>
      <address>
        <city>Brisbane</city>
        <zip>QLD 4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg</name>
      <address>
        <city>Nürnberg</city>
        <state>Bavaria</state>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sant'Andrea Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Than Martin, MD</last_name>
      <email>martin@thanstedman.onmicrosoft.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Silesia</name>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Morawiec, MD</last_name>
    </contact>
    <investigator>
      <last_name>Beata Morawiec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Miro, MD</last_name>
      <phone>0034-93 227 54 00</phone>
      <email>OMIRO@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Oscar Miro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco J Martín, MD</last_name>
      <email>fjjms@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Francisco J Martín, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baselland</name>
      <address>
        <city>Liestal</city>
        <state>Baselland</state>
        <zip>4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Geigy, MD</last_name>
      <phone>0041 61 92 52 248</phone>
      <email>nicolas.geigy@ksli.ch</email>
    </contact>
    <investigator>
      <last_name>Nicolas Geigy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spital Lachen</name>
      <address>
        <city>Lachen</city>
        <state>Schwyz</state>
        <zip>8853</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Luzern Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Christ, Prof.</last_name>
      <email>michael.christ@luks.ch</email>
    </contact>
    <investigator>
      <last_name>Michael Christ, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmar Keller, MD</last_name>
      <phone>+41-(0)44 255 24 30</phone>
      <email>Dagmar.Keller@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Dagmar Keller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Czechia</country>
  </removed_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 5, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Christian Müller, MD</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Syncope</keyword>
  <keyword>Unconsciousness</keyword>
  <keyword>Syncope, vasovagal, neurally-mediated</keyword>
  <keyword>Syncope, cardiogenic</keyword>
  <keyword>Cardiac arrhythmia</keyword>
  <keyword>Sudden cardiac death</keyword>
  <keyword>Syncopal episode</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syncope</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

